伦蛋白酶1介导的代谢重编程促进前列腺癌的进展
Mengfei Yao1,2, Xingming Zhang1, Tianqi Wu3
1Cancer Institute, Shanghai Urological Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Cell death & disease
|February 19, 2025
概括
伦蛋白酶1 (LONP1) 的过度表达通过改变细胞代谢促进前列腺癌 (PCa) 的进展. 准LONP1可能为PCa患者提供新的治疗策略.
科学领域:
- 线粒体生物学 线粒体生物学
- 癌症代谢 癌症代谢
- 分子瘤学分子瘤学
背景情况:
- 隆蛋白酶1 (LONP1) 调节线粒体功能和蛋白质稳定.
- 异常的LONP1表达与各种癌症有关,但其在前列腺癌 (PCa) 中的作用尚不清楚.
研究的目的:
- 研究LONP1在前列腺癌进展中的作用和分子机制.
- 确定PCa患者LONP1表达和临床病理特征之间的关系.
主要方法:
- 使用PCa模型进行体外和体外研究.
- 对PCa患者数据的分析.
- 在基因工程小鼠模型中进行转录和蛋白质组分析.
- 调查LONP1与线粒体酸盐载体1 (MPC1) 的相互作用.
主要成果:
- LONP1过度表达与PCa的不良临床病理特征和不良预后相关.
- LONP1通过将新陈代谢从氧化酸化转移到有氧糖解来促进PCa的扩散,入侵和转移.
- LONP1直接降解MPC1,抑制三碳酸 (TCA) 循环并增强PCa的进展.
- 过度表达LONP1降低了NADH:ubiquinone氧化还原酶的活性,损害了线粒体ATP合成并促进了转移.
结论:
- 由LONP1驱动的代谢重编程对于PCa进展至关重要.
- 准LONP1介导的线粒体通路为前列腺癌提供了潜在的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The Proteasome
8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


